Bringing Targeted Alpha
Therapies to Patients

Andrew is a founder and CEO of AdvanCell. Prior to AdvanCell, Andrew led investment activities for Riverland Capital, a private investment firm, where as a founder and director he focused on investing in China.

Andrew is a director of G2 Therapies, a spinout from the Garvan Institute, and is a director of CGI Glass Lewis, the Australian affiliate of Glass Lewis, a corporate governance advisory firm. Andrew was a director and shareholder of Yuan Chuan Radio (sold to Shanghai-listed Orient Securities), ASX-listed Hostworks Group (sold to Broadcast Australia), amongst other listed and private companies.

Andrew began his career at Peregrine Investments in Hong Kong in 1997 and holds a Bachelor of Arts degree from University of California, Berkeley.

Andrew is an experienced investor in healthcare and is responsible for business development for AdvanCell and corporate activities for the Company.

Simon completed a PhD in Chemistry at the University of Nottingham in 2012 where his study was focused on the use of nuclear magnetic resonance spectroscopy to understand the spatial organisation of ionic liquids. Following his PhD, Simon moved to the University of Cambridge as a Research Fellow focused on the discovery of magnetic resonance imaging biomarkers of neurodegeneration in Huntington's Disease.

Simon moved to Australia in 2013 to take up a position as a Research Fellow at the University of Queensland focused on the development of targeted radionuclide therapies for primary brain cancers. In this position Simon developed a keen interest in the field of nuclear medicine and has developed a portfolio of active research in this field.

Simon moved to CSIRO in 2018 to lead a program of research in targeted alpha therapy development and remains a visiting scientist.

Simon joined AdvanCell in 2021 to realise the potential of the AdvanCell's targeted alpha therapy portfolio.

‍

Dr Danielle Meyrick has over two decades experience in the development and clinical delivery of radiopharmaceuticals. She holds a PhD in Radiopharmaceutical Chemistry and a Doctor of Medicine and previously held the role of Chief Medical Officer, Asia Pacific, for Telix Pharmaceuticals, where she led the clinical science program globally and was responsible for medical affairs in the Asia Pacific region.

Danielle has held senior roles across the public, university and private sectors, from start-ups through to multinationals, and has strong clinical development track record in a number of regulatory settings, including the US and China, as well as commercial radiopharmaceutical product launch experience in Asia Pacific markets.

Danielle has served on councils and committees for the Australian Institute of Nuclear Science and Engineering and ANSTO, has published peer-reviewed articles and technical reports across a breadth of topics in chemistry and medicine and currently serves as non-executive director on the board of Breast Cancer Care WA.  

Dr. Tung has over two decades of experience in healthcare and is an accomplished, innovative, and strategic financial executive. As a key member of the senior executive team at multiple publicly traded biopharma companies, he helped drive corporate strategic initiatives and operational execution. He is adept at financial and market analyses, which have resulted in business development and capital financing deals, with a proven history of managing relationships across the investment community. He was named to the Institutional Investor All-America Executive Team 2018-2020.

Prior to industry, Michael served as an analyst and portfolio manager at various investment firms focused on all healthcare subsectors including biopharmaceuticals, medical devices, and healthcare services. He has a proven track-record of fundamental analysis, portfolio construction, risk management, and superior returns.

Dr. Tung completed the combined MD/MBA program at Tufts University School of Medicine and Brandeis University and is a licensed physician in Massachusetts and New York.

Professor Rose has over 25 years’ experience in clinical R&D within the academic sector along with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national science agency. He works closely with clinicians developing the next generation of molecular imaging, therapeutic and diagnostic platforms targeting oncology sector. Before joining AdvanCell, Prof Rose was director of a prestigious CSIRO Future Science Platform, a highly successful $35m research program with over 30 FTE scientific staff at the PhD level to drive innovation in the Medical Technologies and Pharmaceuticals sector. This included targeting the development of novel theranostic platforms for improved delivery of novel alpha radioligand therapies for difficult to treat cancers.

During this career, Prof Rose has made a significant contribution to obtaining competitive funding from various national medical research funding bodies (NHMRC, MRFF), state government R&D initiatives, the international pharmaceutical industry and private medical service providers. In terms of impact on health, he introduced to Australia a new PET tracer (F18-FEOBV) to measure cholinergic function in dementia patients and was instrumental in establishing clinical molecular imaging research program using MRI, F18-FDOPA and F18-FMISO PET to improve care pathways for patients with brain cancer. Prof Rose has played a major role of bringing new liquid biopsy diagnostic tests to the clinic including the development of NeuroLiB; the first epigenetic ccfDNA assay for detecting neural injury currently being validated through a prospective clinical trial. He was also instrumental in establishing a $5 million theranostics discovery R&D program with GenesisCare, the largest private providers of cancer care services in Australia. Prof Rose has published more than 240 manuscripts in international peer reviewed journals. In terms of general citation indices, his work has been cited 11900 times and his h-index is 52.

Dr Kuan received his PhD in the field of synthetic organic chemistry from the University of Adelaide in 2016 studying biomimetic synthesis of marine natural products. He joined AdvanCell in October 2021 and is currently Director of Operations.
Prior to joining the company, Dr. Kuan was the Head of Chemistry and Product Development at Clarity Pharmaceuticals, where he led the company’s radiopharmaceutical product development and manufacturing operations across all stages of clinical development. Dr. Kuan held various roles of increasing responsibility at the Molecular Imaging and Therapy Research Unit (MITRU), a TGA licensed cyclotron facility belonging to the South Australian Health and Medical Research Institute (SAHMRI).

Dr. Kuan has extensive experience in the implementation and supply of Investigational Medicinal Products for clinical trials and the development of radiometals on cyclotron solid targetry systems.

He holds a patent for Formulations of PSMA Imaging Agents (Australian Patent No. AU 2019901765) and is a Member of the Royal Australian Chemistry Institute (MRACI) and the Australian and New Zealand Society of Nuclear Medicine (ANZSNM)

Dr Tieu holds a PhD in Chemistry from the University of Adelaide and completed a post-doctoral fellowship at the University of Sydney where he developed novel radiopharmaceuticals. He joined AdvanCell in October 2021 as the Head of Chemistry.

Dr Tieu has over 11 years’ experience in drug development, project management and GMP manufacturing. Prior to joining AdvanCell Isotopes, Dr Tieu was the Senior Research Radiochemist at South Australian Health and Medical Research Institute, with responsibility for managing the development of over a dozen radiopharmaceutical and radioisotope products. His role also included scientific contribution to numerous chemistry, radiation and pre-clinical studies. During this period, he was part of a team who helped develop several radiopharmaceuticals including [18F]FDOPA, MK6240, [64Cu]Cu-peptides, [64Cu]Cu-ATSM, [89Zr]Zr-mAbs and production of various imaging isotopes including 68Ga, 89Zr, 45Ti and ²⁰³Pb.

Dr Tieu also has experience with manufacturing of 89Zr-mAbs for a first in human Phase 1 clinical trials. He has 26 publications and 2 patents with his work has been cited more than 443 times. His h-index is 13.   Dr Tieu is a current member of the Australian and New Zealand Society of Nuclear Medicine.

Julian has over 20 years of expertise working with & managing nuclear & radioactive materials. He has a PhD in chemical physics (ANU), and over 10 years of experience developing IP on the innovative uses of radiation and radioactive materials. Julian held scientific roles at CSIRO, the Defence Intelligence Organisation, and at the Australian Nuclear Science and Technology Organisation (ANSTO).

Julian served as Nuclear Attaché in the Australian Embassy in Vienna, representing Australia on technical nuclear matters at the UN’s International Atomic Energy Agency.

Vanessa has over 15 years’ experience in medical diagnostics and devices specialising in the establishment and maintenance of quality management systems required for regulatory market access (TGA, FDA, Health Canada, MHRA, ANVISA, PMDA) and the commercialisation of medical technology involving the establishment of global distribution partners and marketing plans for national and multinational, ASX listed and private companies.

Vanessa has also held leadership roles in manufacturing, successfully implementing lean manufacturing principles to achieve operational excellence in manufacturing plants and distribution centres. Vanessa holds a Bachelor of Biotechnology and a Graduate Diploma in Management, and is currently completing a Master of Business Administration.

Stephen completed a PhD in synthetic organic Chemistry at the University of Wollongong in 2006, derivatising the benzylisoquinoline S-reticuline in order to explore its native chemotherapeutic properties.

Following graduation, Stephen completed a post-doctoral fellowship in radiochemistry at ANSTO. The focus of his research was the development of [18F]F-labelled compounds for imaging metastatic melanoma and αvβ3 integrins. The most successful of these compounds was Mel50 which underwent first-in-man studies.    

Stephen began working as Principal Radiochemist in the Department of Nuclear Medicine at the Royal Brisbane and Women’s Hospital in 2011. He introduced the following validated tracers into the clinical service and research programs at RBWH: [18F]FDG, [18F]FMISO, [18F]FDOPA (electrophilic and nucleophilic syntheses), [68Ga]Dotatate, GE-216, and was a member of the team that successfully obtained a manufacturing license for [18F]FDG from the TGA.  

Stephen was recruited by Liverpool Hospital (Sydney) in 2017 and worked as Principal Hospital Scientist in the team that completed the cyclotron facility build and commissioning. He introduced [18F]FDG, [18F]-PSMA-1007, Na[18F]F, [68Ga]Ga-PSMA, [177Lu]LuDotatate and [177Lu]LuPSMA into the clinical service and research programs at Liverpool Hospital. After moving to RPA Hospital in Sydney Stephen worked for NSW Health as Principal Hospital Scientist until September 2022 when he joined AdvanCell as Head of Production.

Sheruna completed a PhD in Medical Radiation Science from the University of Sydney in 2010 and has over 15 years' experience in radiopharmaceutical manufacturing and registration. She has a deep understanding of the sterile manufacturing and regulatory requirements specifically in this area.

Sheruna’s professional career has spanned across clinical Nuclear Medicine, including research and development, facility design, sterile manufacturing and supply of radiopharmaceuticals in both the private and public health sectors.

She brings specific skills and background to AdvanCell in governance, risk management and radiopharmaceutical science (RPS) and drug registration.

Sheridan has more than eight years’ experience in radiation safety and regulatory affairs management including serving as CSIRO’s Chief Radiation Safety Officer for almost four years before joining AdvanCell in March 2022. Sheridan completed her Honours degree in Chemistry at Flinders University in 2009 with a focus on the development of analytical methods for anticonvulsant pharmaceuticals with Forensic Science South Australia.

She started with CSIRO in 2010 as an analytical research technician in CSIRO Land and Water’s environmental contaminants team before transitioning to CSIRO’s Health, Safety and Environment team in 2016. Sheridan was instrumental in driving key regulatory and radiation safety initiatives within CSIRO, including leading a multi-million-dollar project to consolidate and characterise CSIRO’s legacy waste holdings.

Dr Canever earned a master’s degree in chemistry from the University of Padova (Italy), and a PhD in chemistry from Victoria University of Wellington, New Zealand, with a thesis titled “Electrode nanomaterials and electrolytes for Aluminium-ion batteries”. As an early-career researcher, he authored several academic publications originating from his work. He joined the AdvanCell team in early 2021 and has recently taken on a full-time position as a research scientist.

Before joining AdvanCell, he worked as a Postdoctoral Research Associate at the University of Newcastle, where he conducted research in the field of energy storage and nanomaterials, both through individual work and the supervision of small research project by undergraduate students. As part of this position, he contributed to the supervision of an internship sponsored by AdvanCell.

Thomas completed a PhD in Biological Sciences and Biochemistry at the University of Tours in 2013 where his research was focused on the involvement of proteases in lung cancer progression. In 2014, Thomas moved to the Queensland University of Technology- Australian Prostate Cancer Research Centre as a Research Fellow to work on the roles of proteases in prostate cancer progression.

In 2018, Thomas started to work at the Mater Research Institute – University of Queensland as a Senior Research Officer focused on the development and preclinical validation of targeted therapies for pancreatic, ovarian and breast cancers. Thomas has been involved in various translational projects conducting to multiple high-impact publications, novel preclinical models and the progression of several agents to clinical testing.

Thomas joined AdvanCell as Preclinical Development Manager in October 2022 to push forward the preclinical development of the AdvanCell's targeted alpha therapy portfolio.

Thien holds a Medical Engineering degree from QUT and has held multiple engineering roles across R&D, Manufacturing Operations, Field Service, and Management in various clinical and biotech settings.

At the Austin Hospital’s Department of Molecular Imaging & Therapy, Thien was responsible for maintaining and improving the radiopharmaceutical production facilities. In addition to scaling up the existing clinical production capacity, he developed an award-winning design for an automated 86Y radiosynthesiser.

In a previous role, Thien was instrumental in enabling the growth of manufacturing operations, managing multiple key projects including the construction of GMP compliant manufacturing facilities.

Thien joined AdvanCell in November 2022 to drive the development of the AdvanCell ²¹²Pb Generator and build the inhouse engineering function of AdvanCell.

Mei completed a BSc in Chemistry at King’s College London (University of London, UK) and Postgraduate Diploma in Management Studies (DMS) at the University of Westminster, UK. After graduation, Mei started her career as a medicinal chemist for GSK before moving into Regulatory Affairs, working for various UK pharmaceutical companies then for Singapore’s regulatory body, the Health Sciences Authority (HSA).

Following a move to Australia, Mei joined a medical device company which broadened her Regulatory skills and expanded her knowledge in Quality. Mei then took on Quality roles within a GMP environment, initially in Quality Systems for pharmaceutical manufacturing and then in Quality Assurance for biologics manufacturing. Mei joined AdvanCell in September 2022 as Quality Associate.

Naomi is a clinical trials specialist with over 20 years of experience across site, biotech and clinical research organisations. She completed a Bachelor of Applied Science (Class Ia honours) and PhD at The University of Queensland.

Naomi has held various roles within the industry including clinical research associate, local and global project manager and medical writer. She has experience managing studies across Asia Pacific, the United States and Europe, and has previously been involved in the development of investigational radiopharmaceuticals.

Naomi joined AdvanCell in December 2022 to manage clinical operations for AdvanCell’s targeted alpha therapy portfolio.

Aimee holds a PhD in chemical science with a focus on peptide chemistry, as well as a MPhil and BSc (Molecular & Drug Design) from the University of Adelaide. Aimee’s research degrees focused on the design of peptides with defined 3-dimensional structure to inhibit biologically important protein interactions. In particular, characterising peptides that bind the human protein PCNA, toward development of a broad spectrum cancer therapeutic.

While at the University of Adelaide, in conjunction with the ARC Centre of Excellence for Nanoscale Biophotonics (CNBP), Aimee worked on projects to develop materials for the detection of biologically important small molecules or proteins.

Aimee worked as a postdoctoral research fellow at the University of Auckland for ‘next generation antibiotics’ in developing methods for the total synthesis of peptide natural products with antimicrobial activity.

Aimee has also been involved with the University of Adelaide Sciences Alumni committee and served as an ECR representative for the Executive Management Committee of the CNBP. Aimee has over 14 peer-reviewed journal publications.

Born and raised in Brisbane, Phillip attended the University of Queensland, completing a Bachelor of Science with a major in Chemistry. Following his studies, Phillip worked as a Radiochemist for several years, predominately supplying Technetium based compounds for diagnostic imaging. During this time, Phillip developed a passion for radiochemistry which led Phillip to join AdvanCell.

Camila completed a Bachelor of Forensic Science majoring in Chemistry from the University of Technology Sydney in 2021. Her area of expertise is in the GMP production of radiopharmaceuticals and has held technical roles in Quality Assurance and Radiochemistry.

Camila joined AdvanCell as a Production Scientist in May 2023.

Feifei Liu completed a Bachelor of Pharmaceutical Engineering from Central South University (China), and a Master’s degree in Chemical and Biomolecular Engineering from The University of Sydney. Following her master education, Feifei worked in the pharmaceutical industry for several years, where she focused on implementing good GMP/cGMP to ensure the medicinal products were consistently produced and controlled according to quality standards. She is skilled in 21 CFR part 210/211 (FDA), Directive 2001/83/EC (EU), 2010 China GMP guidelines, and ICH Quality guidelines.

Before joining AdvanCell, Feifei worked as a Research Assistant at the University of Queensland, where she was involved in the preclinical research for industry collaborated projects at Centre for Advanced Imaging (CAI) including studies sponsored by AdvanCell. Feifei joins AdvanCell as Preclinical Scientist to assist the preclinical development of the AdvanCell's Targeted Alpha Therapy portfolio.

Feifei is currently completing a PhD degree in Biomedical science at The University of Queensland. Her research is focused on targeted delivery of novel immune-boosting peptides to the tumour microenvironment using designed nanomedicines as a method to suppress cancer growth.

Simran obtained her Bachelor's degree in Pharmaceutical Science and a Postgraduate Diploma in Health Research from the University of South Australia.

As a Research Assistant at the South Australian Health and Medical Research Institute, Simran specialised in the production of radiopharmaceuticals manufactured according to Good Manufacturing Practice (GMP). Simran has held various other roles in Production and Quality Assurance and Control at Baxter for the manufacture of chemotherapy and nutrition products.

Simran’s academic achievements and professional experience has positioned her as a highly skilled and knowledgeable individual in the field of pharmaceutical science.

‍